Table of Contents

• Overview of Apixaban trials
• Patient groups studied
• Trial phases and study design
• Main endpoints and what they mean
• Key trials by clinical area
• What Apixaban is compared with
• Patient-friendly terms used in the trials

Overview of Apixaban trials

These studies investigate Apixaban in many settings, including clot prevention, stroke prevention, and treatment comparisons in special patient groups.^[1] The trial data show both completed and authorised studies, with most being interventional trials.^[1]

Patient groups studied

Some trials include healthy volunteers to test whether two formulations of Apixaban behave the same in the body.^[1] Other studies include people with atrial fibrillation, venous thromboembolism, chronic kidney disease stage 5, short bowel syndrome, heart valve disease, and patients after surgery.^[1]

Several trials focus on special situations where clotting and bleeding risks are both important, such as after cardiac surgery, after knee or hip replacement, after left atrial appendage closure, or after transcatheter aortic valve implantation.^[1] Some studies also look at people with cancer-associated venous thromboembolism, venous malformation, intra-cardiac thrombus, or acute ischemic stroke.^[1]

Trial phases and study design

The dataset includes Phase 1 bioequivalence studies in healthy volunteers, which look at whether two Apixaban products give similar blood exposure.^[1] It also includes Phase 2 trials, which are smaller studies that explore early efficacy or safety questions, such as pain in venous malformations or clot prevention after knee replacement.^[1]

Most of the larger studies are Phase 3 trials, which compare Apixaban with another treatment, placebo, or no anticoagulation in real patient groups.^[1] One study is listed as Phase 4, and one study is listed as Low Intervention, showing that the trial set includes more than one type of research design.^[1]

Main endpoints and what they mean

The trial endpoints often measure whether a patient has a clot, a bleed, or both.^[1] Common outcomes include stroke, systemic embolism, venous thromboembolism, major bleeding, and death.^[1]

Some studies use imaging or lab measures instead of clinical events alone, such as AUC, Cmax, anti-Xa levels, thrombus resolution on echocardiography, or leaflet thickening on cardiac CT.^[1] In simple words, these tests help researchers see how much drug reaches the blood, how the body handles it, and whether a clot or valve problem changes over time.^[1]

Key trials by clinical area

In atrial fibrillation, several large trials compare Apixaban with other anticoagulants or with no anticoagulation to study stroke prevention, bleeding, and overall clinical benefit.^[1] Examples include studies in frail older patients, patients with chronic kidney disease stage 5, patients after cardiac surgery, and patients with atrial fibrillation after stress or after left atrial appendage closure.^[1]

In surgical settings, Apixaban is being studied for clot prevention after knee replacement, hip surgery, abdominal surgery, colorectal polypectomy, and transcatheter aortic valve implantation.^[1] These studies ask whether Apixaban can lower clot risk without causing too much bleeding.^[1]

In special disease groups, trials examine Apixaban in short bowel syndrome, Roux-en-Y gastric bypass, venous malformations, intrahepatic non-cirrhotic portal hypertension, intra-cardiac thrombus, and autoimmune hemolytic anemia.^[1] These studies help researchers understand whether Apixaban works the same way in people whose body or disease may change clotting risk or drug handling.^[1]

What Apixaban is compared with

Apixaban is often compared with warfarin, aspirin, enoxaparin, placebo, or other direct oral anticoagulants such as rivaroxaban, dabigatran, and edoxaban.^[1] Some trials compare Apixaban with no anticoagulant treatment, while others compare it with a different clot-prevention strategy after surgery or in chronic disease.^[1]

Several studies also use Apixaban as a reference treatment when testing another medicine, which helps researchers see whether the new treatment is similar, better, or less safe.^[1]

Patient-friendly terms used in the trials

• Bioequivalence means two versions of a medicine are shown to act similarly in the body.^[1]

• Composite endpoint means the study counts several related events together as one main result.^[1]

• Thromboembolic event means a harmful clot that blocks blood flow, such as stroke or pulmonary embolism.^[1]

• Bleeding endpoint means the trial is checking for bleeding events, often including major bleeding and clinically relevant non-major bleeding.^[1]

• Randomized means participants are assigned by chance to different study groups.^[1]